Toggle navigation
Home
Search
Services
Blog
Contact
About
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L.
Genaissance Pharmaceuticals, Inc., New Haven, CT, United States
Search 4 grants from Kevin Bentley
Search grants from Genaissance Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
A New Filter Paper Technology for Flavivirus Collection, Shipping, and Analysis
SMA Biomarkers in the Immediate Post-natal Period of Development
Point of Care Adult Stem Cell Isolation
Point of Care Adult Stem Cell Isolation
Endometriosis and Retinoids
Recently added grants:
Store-operated Ca2+ signaling in kidney glomerular mesangial cells
Conceptual and mechanistic insights into the development of diet-induced obesity through disruption of hepatic circadian rhythms by the gut microbiome
Copper and iron in nutritional immunity
Developing a biomarker panel to assess choline nutritional status
Generation of New Mouse Models of Low Nephron Numbers to Understand Pathogenesis of AKI and CKD in Humans Born Preterm
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
9R44HL059114-02
Application #
2423742
Study Section
Special Emphasis Panel (ZRG2-SSS-Y (15))
Project Start
1997-08-29
Project End
1999-07-31
Budget Start
1997-08-29
Budget End
1998-07-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Genaissance Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511
Related projects
NIH 1998
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
NIH 1997
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
Comments
Be the first to comment on Kevin Bentley's grant